



PRESS RELEASE

For Immediate Release:

Date: March 31, 2017

Allurion Repays Massachusetts Life Sciences Center

Natick company has commercialized a gastric balloon technology to combat obesity

Natick, MA - The Massachusetts Life Sciences Center (MLSC) and Natick-based Allurion Technologies announced today that the company, which was awarded a \$750,000 Accelerator loan from the MLSC in 2011, has repaid the loan with interest after a successful funding round from private investors. Allurion's repayment to the MLSC totaled \$1,115,824.

Allurion's flagship product is the Elipse™ gastric balloon, a procedureless™ medical device for weight loss. The Elipse device comprises a balloon made of thin polymer film that is delivered in a 15-minute outpatient visit without need for anesthesia or surgery. It is filled with water and resides in the stomach for four months, enabling weight loss which averages between 10% and 15% of starting weight. At the end of therapy, a patented opening mechanism is automatically activated, allowing the device to empty and pass naturally.

At the time of the MLSC loan Allurion had three employees and was still developing its technology. The company now has more than 20 Massachusetts-based employees. Its product, which has not yet been approved by the FDA, is currently available in select weight loss centers in France, Italy, Belgium, Greece, the U.K., Spain, Kuwait, Saudi Arabia and Qatar, with plans for a U.S. clinical trial commencing in 2017.

Allurion has also served as a host company for the MLSC's Internship Challenge Program, hosting seven interns to date for which it has or will receive salary reimbursement through the MLSC.

Allurion's Chairman and CEO Jonathan Wecker said "the Accelerator loan from the MLSC did exactly what we needed – it accelerated our development and allowed us to build a case for traditional private investment. We are grateful to the MLSC for its early confidence in our potential and are proud to have returned the funds, with interest, to the Commonwealth."

"Our Accelerator Loan Program seeks to de-risk promising early-stage companies and make them more attractive to private investors," said Massachusetts Life Sciences Center President & CEO Travis McCready. "We were pleased to provide early financial and workforce support to Allurion, both through our Accelerator Program and our Internship Challenge Program, as they

built their company and developed this promising technology. We look forward to seeing the ongoing positive impact that their technology will have on patients around the world.”

“The biotech sector is thriving across the state, and Allurion is a terrific example of innovation and entrepreneurship here in MetroWest,” said Senator Karen E. Spilka (D-Ashland). “This is a MLSC success story of a targeted investment in the life sciences cluster creating jobs and advancing critical technology. I look forward to continuing the state’s partnership with Allurion and other innovative life sciences companies in our community.”

“It is great to see that the MetroWest continues to be a leader in the research and development of life sciences,” said Representative David Linsky (D-Natick). “I look forward to the future projects that will come out of Allurion.”

About the Massachusetts Life Sciences Center

The Massachusetts Life Sciences Center (MLSC) is an investment agency that supports life sciences innovation, education, research & development and commercialization. The MLSC is charged with implementing a \$1-billion, state-funded investment initiative. These investments create jobs and support advances that improve health and well-being. The MLSC offers the nation’s most comprehensive set of incentives and collaborative programs targeted to the life sciences ecosystem. These programs propel the growth that has made Massachusetts the global leader in life sciences. The MLSC creates new models for collaboration and partners with organizations, both public and private, around the world to promote innovation in the life sciences. Learn more at <http://www.masslifesciences.com/>

About Allurion Technologies

Allurion Technologies is dedicated to developing less invasive treatments for overweight and obese individuals. The company's flagship product, the Elipse device, is an intragastric balloon that resides in the stomach, enabling weight reduction. Allurion is funded by Romulus Capital, a Cambridge Massachusetts based venture fund, and private investors. Learn more about the Elipse device and Allurion online at <http://www.allurion.com> or on Twitter @alluriontech.

Contacts:

Darren Brandt for Allurion

Phone: 212-446-1861 **Email:** dbrandt@sloanep.com

Robert Ramos, MLSC Senior Marketing Coordinator

Phone: 781-373-7732 **E-mail:** rros@masslifesciences.com

MLSC Disclaimer: This announcement is not intended to be a commercial endorsement of any products or services provided or developed by the entities referenced in this release.

###